Literature DB >> 26595420

Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab.

Giovanna Scapin1, Xiaoyu Yang2, Winifred W Prosise1, Mark McCoy1, Paul Reichert1, Jennifer M Johnston1, Ramesh S Kashi3, Corey Strickland1.   

Abstract

Immunoglobulin G4 antibodies exhibit unusual properties with important biological consequences. We report the structure of the human full-length IgG4 S228P anti-PD1 antibody pembrolizumab, solved to 2.3-Å resolution. Pembrolizumab is a compact molecule, consistent with the presence of a short hinge region. The Fc domain is glycosylated at the CH2 domain on both chains, but one CH2 domain is rotated 120° with respect to the conformation observed in all reported structures to date, and its glycan chain faces the solvent. We speculate that this new conformation is driven by the shorter hinge. The structure suggests a role for the S228P mutation in preventing the IgG4 arm exchange. In addition, this unusual Fc conformation suggests possible structural diversity between IgG subclasses and shows that use of isolated antibody fragments could mask potentially important interactions, owing to molecular flexibility.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26595420     DOI: 10.1038/nsmb.3129

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  39 in total

1.  Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding.

Authors:  W L Martin; A P West; L Gan; P J Bjorkman
Journal:  Mol Cell       Date:  2001-04       Impact factor: 17.970

2.  Mapping monoclonal antibody structure by 2D 13C NMR at natural abundance.

Authors:  Luke W Arbogast; Robert G Brinson; John P Marino
Journal:  Anal Chem       Date:  2015-03-09       Impact factor: 6.986

3.  [The primary structure of crystallizable monoclonal immunoglobulin IgG1 Kol. II. Amino acid sequence of the L-chain, gamma-type, subgroup I].

Authors:  H D Kratzin; W Palm; M Stangel; W E Schmidt; J Friedrich; N Hilschmann
Journal:  Biol Chem Hoppe Seyler       Date:  1989-03

Review 4.  The impact of glycosylation on the biological function and structure of human immunoglobulins.

Authors:  James N Arnold; Mark R Wormald; Robert B Sim; Pauline M Rudd; Raymond A Dwek
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

5.  Single Transition-to-single Transition Polarization Transfer (ST2-PT) in [15N,1H]-TROSY.

Authors:  K V Pervushin; G Wider; K Wüthrich
Journal:  J Biomol NMR       Date:  1998-08       Impact factor: 2.835

Review 6.  Recognition of immunoglobulins by Fcgamma receptors.

Authors:  Sergei Radaev; Peter Sun
Journal:  Mol Immunol       Date:  2002-05       Impact factor: 4.407

7.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

8.  A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody.

Authors:  S Angal; D J King; M W Bodmer; A Turner; A D Lawson; G Roberts; B Pedley; J R Adair
Journal:  Mol Immunol       Date:  1993-01       Impact factor: 4.407

9.  The Fab conformations in the solution structure of human immunoglobulin G4 (IgG4) restrict access to its Fc region: implications for functional activity.

Authors:  Lucy E Rayner; Gar Kay Hui; Jayesh Gor; Richard K Heenan; Paul A Dalby; Stephen J Perkins
Journal:  J Biol Chem       Date:  2014-05-29       Impact factor: 5.157

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  68 in total

1.  Structure of a Therapeutic Full-Length Anti-NPRA IgG4 Antibody: Dissecting Conformational Diversity.

Authors:  Michaela Blech; Stefan Hörer; Alexander B Kuhn; Sebastian Kube; Hendrik Göddeke; Hans Kiefer; Yuguo Zang; Yannic Alber; Stefan M Kast; Martin Westermann; Mark D Tully; Lars V Schäfer; Patrick Garidel
Journal:  Biophys J       Date:  2019-04-05       Impact factor: 4.033

2.  In-silico prediction of concentration-dependent viscosity curves for monoclonal antibody solutions.

Authors:  Dheeraj S Tomar; Li Li; Matthew P Broulidakis; Nicholas G Luksha; Christopher T Burns; Satish K Singh; Sandeep Kumar
Journal:  MAbs       Date:  2017-01-26       Impact factor: 5.857

3.  In Silico Prediction of Diffusion Interaction Parameter (kD), a Key Indicator of Antibody Solution Behaviors.

Authors:  Dheeraj S Tomar; Satish K Singh; Li Li; Matthew P Broulidakis; Sandeep Kumar
Journal:  Pharm Res       Date:  2018-08-20       Impact factor: 4.200

Review 4.  Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?

Authors:  Markella Konstantinidou; Tryfon Zarganes-Tzitzikas; Katarzyna Magiera-Mularz; Tad A Holak; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2018-02-23       Impact factor: 15.336

Review 5.  Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.

Authors:  Teresa C Longoria; Krishnansu S Tewari
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-08-16       Impact factor: 4.481

6.  Pembrolizumab for the treatment of advanced melanoma.

Authors:  Michael C Burns; Aidan O'Donnell; Igor Puzanov
Journal:  Expert Opin Orphan Drugs       Date:  2016-06-07       Impact factor: 0.694

7.  The solution structure of the human IgG2 subclass is distinct from those for human IgG1 and IgG4 providing an explanation for their discrete functions.

Authors:  Gar Kay Hui; Antoni D Gardener; Halima Begum; Charles Eldrid; Konstantinos Thalassinos; Jayesh Gor; Stephen J Perkins
Journal:  J Biol Chem       Date:  2019-05-14       Impact factor: 5.157

Review 8.  Impact of the Protein Data Bank on antineoplastic approvals.

Authors:  John D Westbrook; Rose Soskind; Brian P Hudson; Stephen K Burley
Journal:  Drug Discov Today       Date:  2020-02-14       Impact factor: 7.851

Review 9.  Clinical Immunogenicity Risk Assessment for a Fusion Protein.

Authors:  Gizette Sperinde; Diana Montgomery; Daniel T Mytych
Journal:  AAPS J       Date:  2020-04-03       Impact factor: 4.009

Review 10.  Pembrolizumab in classical Hodgkin's lymphoma.

Authors:  Joseph Maly; Lapo Alinari
Journal:  Eur J Haematol       Date:  2016-05-30       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.